AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
CDSCO Tightens Action Against Banned Antibiotics After Shrimp Export Rejections Jump 43%
The Central Drugs Standard Control Organisation (CDSCO), under India's Ministry of Health and Family Welfare, has issued a directive to all State and Union...
Solaris Pharma Launches Generic Briviact®️ to Improve Access to Epilepsy Treatment
Solaris Pharma has launched brivaracetam tablets — the generic equivalent of UCB's Briviact® — marking a notable pivot for a company long anchored in...
XOCOVA®️ Becomes First-Ever Oral Pill Approved to Prevent COVID-19 After Exposure
A historic milestone in pandemic preparedness arrived this week as the U.S. Food and Drug Administration granted approval to XOCOVA® (ensitrelvir) — the world’s...
AstraZeneca’s Ultomiris®️ Cuts Proteinuria by 43.4% in Phase – 3 Trial
Alexion, AstraZeneca Rare Disease, announced positive results from a prespecified interim analysis of the global Phase III I CAN trial. The data demonstrate...
Lupin Gets U.S. FDA Approval for Ranluspec™ to Treat Retinal Disorders
Lupin Limited has secured U.S. FDA approval for Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Genentech’s Lucentis® — a milestone that reshapes patient access to sight-saving biologics across...
